[144] ARGAN INC SEC Filing

Rhea-AI Filing Summary

Argan, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 11,802 common shares acquired by stock option exercise on 06/09/2025. The filing lists the broker as Fidelity Brokerage Services LLC and shows an aggregate market value of $3,228,909.00 based on outstanding shares of 13,811,575. The approximate date of sale is 09/29/2025 on the NYSE. The filer certifies there is no undisclosed material adverse information and reports no sales of issuer securities in the past three months.

Positive

• Insider exercised stock options on 06/09/2025, demonstrating option realization
• Planned sale details disclosed: 11,802 shares for an aggregate market value of $3,228,909.00 through Fidelity on NYSE (09/29/2025)

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider notice: option exercise followed by planned sale of 11,802 shares worth $3.23M; neutral to market absent other disclosures.

The Form 144 documents an insider exercise of stock options on 06/09/2025 and a proposed sale of those shares through Fidelity on 09/29/2025. The filing provides specific quantities and an aggregate market value of $3,228,909.00. There are no reported sales in the prior three months and the filer affirms no undisclosed material adverse information. This is a standard regulatory disclosure enabling sale under Rule 144 and, on its face, does not introduce new operational or financial data about the company.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 requirements for an officer/director/affiliate sale; compliance-focused and not inherently material.

The filing identifies the nature of acquisition as a stock option exercise and names the broker and sale date. It includes the statutory representation regarding material information and shows no recent sales by the reporting person. As a governance disclosure, it documents an intended transfer of shares by a person subject to insider-sale rules; absent further context about role or pattern of sales, this is a compliance filing rather than a governance event that implies misconduct or material change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street 245 oston MA 02110	11802	3228909.00	13811575	09/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/09/2025	Stock Option Exercise	Issuer			11802	06/09/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Form 144 for AGX disclose?

The filing discloses a proposed sale of 11,802 common shares acquired by stock option exercise on 06/09/2025, to be sold on 09/29/2025 via Fidelity on the NYSE, with an aggregate market value of $3,228,909.00.

Who is the broker handling the proposed AGX sale?

The broker listed is Fidelity Brokerage Services LLC, 245 Summer Street, Boston, MA.

Does the filing report any other sales in the past three months for the filer?

No. The filing states "Nothing to Report" for securities sold during the past three months.

When were the shares acquired by the filer?

The shares were acquired by a stock option exercise on 06/09/2025, and payment was recorded on the same date.

Does the filer assert any undisclosed material information about AGX?

By signing, the filer represents they do not know any material adverse information